Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-2023
CP Sjaarda, L Lau, JT Simpson, R Fattouh… - JAMA Network …, 2023 - jamanetwork.com
Importance Nirmatrelvir-ritonavir is an oral antiviral medication that improves outcomes in
SARS-CoV-2 infections. However, there is concern that antiviral resistance will develop and …
SARS-CoV-2 infections. However, there is concern that antiviral resistance will develop and …
Efficacy of nirmatrelvir and ritonavir for post‐acute COVID‐19 sequelae beyond 3 months of SARS‐CoV‐2 infection
The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
Ensuring widespread and equitable access to treatments for COVID-19
As the COVID-19 pandemic has evolved into its third year, it is important to assess the
medical interventions and public health approaches that have been developed. Given the …
medical interventions and public health approaches that have been developed. Given the …
Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019
Background Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus
ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of …
ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of …
[HTML][HTML] Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …
clinical management and isolation of patients with COVID-19. We evaluated an unselected …
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
L Yan, D Bui, Y Li, N Rajeevan… - Clinical Infectious …, 2024 - academic.oup.com
Background Nirmatrelvir-ritonavir is recommended for persons at risk for severe coronavirus
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …
[HTML][HTML] Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
Background The impact of nirmatrelvir/ritonavir treatment on shedding of viable virus in
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Methods A …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Methods A …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …